VNRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
VNRX is not a good buy right now for an impatient investor. The stock is still in a broader bearish trend (SMA200 > SMA20 > SMA5) and today’s jump looks more like a short-lived bounce near resistance (~0.293–0.332) than a confirmed reversal. With no proprietary buy signals, very low/liquidity options activity, and extremely elevated implied volatility, the risk/reward favors avoiding new entries (and using strength to exit if already holding).
Price/Trend: Despite today’s strong move (close ~0.295 vs 0.251 prior), the primary trend remains bearish with moving averages stacked bearishly (SMA200 > SMA20 > SMA5), implying rallies are still counter-trend. Momentum: RSI(6) ~54.5 is neutral (no strong upside momentum). MACD histogram is negative (-0.0027) but contracting, consistent with a weakening downtrend / bounce attempt rather than a clear uptrend. Levels: Pivot ~0.293 (price is sitting right on it). Near-term resistance at R1 ~0.332 then R2 ~0.355; support at S1 ~0.255 then S2 ~0.232. For an impatient buyer, entry here is “in the middle” (at pivot/resistance zone), not at an obvious low-risk support. Pattern/Short-term odds: Similar-pattern stats imply slightly negative drift over week/month (-1.61% / -2.99%), which doesn’t support chasing.
Intellectia Proprietary Trading Signals
Company-specific: Management previously highlighted multiple partnership discussions around the Nu.Q platform, and Q3 showed revenue growth (+32% YoY). Prior cited agreements with major diagnostics players (Werfen, Hologic) support a long-term commercial narrative.
Technical: MACD negative but contracting plus a strong up-day can sometimes precede a short-term bounce continuation if price clears ~0.332.
Technical overhang: Bearish moving-average stack indicates the broader trend remains down; rallies can fail near resistance (0.293–0.332).
Event/news vacuum: No news in the last week to justify follow-through after the spike.
Options/implied risk: Extremely high implied volatility and thin option volume point to speculative price action and higher odds of snapback.
Positioning/flow: No notable hedge fund or insider trend reported recently.
Latest quarter (2025/Q3): Revenue rose to ~$0.63M (+32.19% YoY), but losses remain large with net income at about -$5.38M (worse by ~7.61% YoY) and EPS at -$0.05 (down ~28.57% YoY). The growth is off a small base and profitability is not improving, so fundamentals don’t support chasing a spike.
Recent trend: Ratings and targets have weakened. Maxim downgraded to Hold from Buy (2025-12-03). H.C. Wainwright kept Buy but cut the price target to $1.50 from $2.50 (2025-11-17). Wall Street pros: Platform/partnership optionality and revenue growth. Wall Street cons: Ongoing sizable losses and lowered targets signal tempered confidence and higher execution risk. Influential/politician activity: No recent congress trading data available; no notable political/influential buying/selling reported in the provided data.
